Release Date: 28/08/17 13:58 Summary: Managing Director's letter to Shareholders Price Sensitive: No Download Document 268.62KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%